Nirav Shah, MD

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Loxo-Lilly
    Topic: 
    Consulting/Advisory Board/Travel
    Date added: 
    03/19/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Miltenyi Biotec
    Topic: 
    Consulting/Advisory Board/Travel
    Date added: 
    03/19/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Kite
    Topic: 
    Advisory Board
    Date added: 
    03/19/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Incyte
    Topic: 
    Consulting
    Date added: 
    03/19/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Janssen
    Topic: 
    Advisory Board
    Date added: 
    03/19/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    BMS-Juno
    Topic: 
    Advisory Board
    Date added: 
    03/19/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Seattle Genetics
    Topic: 
    Advisory Board
    Date added: 
    03/19/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    TG Therapeutics
    Topic: 
    Advisory Board
    Date added: 
    03/19/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Stock
    Ineligible company: 
    Tundra Therapeutics
    Topic: 
    Founder/Scientific Board
    Date added: 
    03/19/2023
  • Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Epizyme
    Topic: 
    Advisory Board
    Date added: 
    03/19/2023
Return to 2023 Annual Summit on Hematologic Cancers: Incorporation of Novel Therapies in Clinical Practice